Crispr and Cas Gene Market to Hit $6.47 Billion by 2030: Coherent Market Insights (CMI)
Crispr and Cas gene are segment of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins (Cas) that act as an acquired immune system in bacteria and archaea defend against foreign genetic elements such as viruses. These genes are majorly used for genome editing applications in various industries including biotechnology and pharmaceutical.
Burlingame, Dec. 04, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, The global crispr and cas gene market was valued at US$ 1.54 Billion in 2023 and is forecast to reach a value of US$ 6.47 Billion by 2030 at a CAGR of 22.8% between 2023 and 2030.
Increasing research and development activities and inorganic strategies by the market players to develop innovative products. Moreover, the market players are utilizing crispr technology to launch products for COVID-19 is expected to propel the market growth over the forecast period. For instance, in September 5, 2023, ERS Genomics Limited, announced a new license agreement with AlgenScribe SAS. This is a non-exclusive licensing agreement granting AlgenScribe access to the ERS CRISPR/Cas9 patent portfolio.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2598
Market Driver:
Increasing Crispr product launches
Increasing product lanches by the market players are expected to drive the crispr and cas gene market growth over the forecast period. For instance, on September 27, 2022, Vertex Pharmaceuticals Incorporated, a biotechnology company, and CRISPR Therapeutics, a biotechnology company headquartered in Zug, Switzerland, announced that Vertex has concluded discussion with the U.S. Food and Drug Administration (FDA), and the U.S. FDA granted exagamglogene autotemcel a rolling review for the potential treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Vertex submitted its Biologics Licensing Application (BLA) for exa-cel for rolling review, in November 2022 and expects to complete the submission by the end of Q1 2023.
On July 27, 2023, Sherlock Biosciences, a CRISPR-based diagnostic technology developer, expected to launch an assay design service that allows users to access the firm’s novel artificial intelligence algorithms and create their own tests.
Market Key Developments:
On February 15, 2022, Intellia Therapeutics, Inc., a genome editing company and ONK Therapeutics Ltd, a company dedicated to developing optimally engineered natural killer (NK) cell therapies to cure patients with cancer, announced a licensing and collaboration agreement. The agreement grants ONK Therapeutics Ltd, a non-exclusive license to Intellia Therapeutics, Inc. proprietary ex vivo CRISPR/Cas9-based genome editing platform and its lipid nanoparticle (LNP)-based delivery technologies to develop up to five allogeneic NK cell therapies.
On May 6, 2021, CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and Nkarta, Inc., a biopharmaceutical company developing engineered NK cell therapies to treat cancer, announced a strategic partnership to research, develop, and commercialize CRISPR/Cas9 gene-edited cell therapies for cancer.
Buy this Complete Business Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2598
Key Market Takeaways:
The global crispr and cas gene market is expected to exhibit a CAGR of 22.8% during the forecast period due to the increasing research and development activities for the development of products. For instance, on September 16, 2022, Editas Medicine, clinical-stage genome editing company, announced positive interim results from an ongoing Phase 1/2 clinical study of NTLA-2002, its second in vivo genome editing candidate. NTLA-2002 is a systemically administered CRISPR candidate being developed for hereditary angioedema (HAE) and is designed to knock out the KLKB1 gene in liver cells, thereby reducing the production of kallikrein protein.
Among application, the genome engineering is expected to dominate the market over the forecast period, and this is attributed to the increasing prevalence of chronic diseases such as cancer. For instance, according to data published by the American Cancer Society in 2020, there were estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the U.S.
Market Opportunity:
On July 18, 2023, Sanofi, a pharmaceutical company, received exclusive license for privately-held Scribe Therapeutics,inc CRISPR X-Editing genome editing technologies to develop in-vivo therapies. On June 1, 2020, Regeneron Pharmaceuticals, Inc., a biotechnology company based in New York, U.S. and Intellia Therapeutics, Inc., a clinical stage biotechnology company based in Massachusetts, U.S., announced an expansion of their existing collaboration to provide regeneron with rights to develop products for additional in vivo CRISPR/Cas9-based therapeutic targets.
Market Cross Sectional Analysis:
Among product type, the vector-based cas segment is expected to be dominant during the forecast period in North America due to the key players focusing on organic strategies, such as the launch of new equipment, which is expected to drive the segment growth over the forecast period.
Ask for Customization: https://www.coherentmarketinsights.com/insight/request-customization/2598
Market Restraint:
According to data published by the University of California, Los Angeles, the possibility for off-target genome editing impacts is the main concern connected to CRISPR/Cas9 technology. Human DNA can undergo site-specific alterations as a result of CRISPR/Cas9 technology. The CRISPR/Cas9 system has been shown to have offtarget effects in addition to cleavage at the precise target region. Due in part to imperfect homologies between gRNA and other parts of the genome, various off-target effects are caused. Additionally, there is a chance that on-target actions will have unintended results.
The key players operating in the global crispr and cas gene market include Thermo Fisher Scientific Inc., Merck KGaA (Sigma-Aldrich), OriGene Technologies, Inc., New England Biolabs, Cellecta, Inc., Agilent Technologies, Inc., Applied StemCell, Inc., Synthego, Genscript, Mirus Bio LLC, Integrated DNA Technologies, Inc., and Mammoth Biosciences, Inc.
Crispr and Cas Gene Market Detailed Segmentation:
By Product Type:
Vector-based Cas
DNA-free Cas
Others
By Application:
Genome Engineering
Disease Models
Functional Genomics
Knockdown/Activation
Others
By End User:
Biotechnology and Pharmaceutical Companies
Academic & Government Research Institutes
Contract Research Organizations
By Region:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Rest of Latin America
Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
Rest of Asia Pacific
Middle East & Africa
South Africa
GCC Countries
Rest of Middle East & Africa
Read complete market research report, "Crispr and Cas Gene Market, By Product, By Application, By End User, By Region, and Segment Forecast 2023-2030", Published by Coherent Market Insights.
Find more related trending reports below:
CRISPR Technology Market, By Product (Enzymes, Kits & Reagents, Guide RNA, and Others), By Application (Biomedical, Agricultural, Industrial, and Others), By End User (Pharmaceutical companies and Biotechnology Companies, Academics and Government Research Institutes, and Others (CROs etc.)), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028
Plasmid DNA Manufacturing Market, By Product Type (Viral Vectors, Plasmid DNA and Non-viral Vectors), By Grade (GMP Grade, R&D Grade and Clinical Grade), By Application (DNA Vaccines, Gene Therapy, Immunotherapy, RNA Vaccines and Others), By Manufacturing Type (Outsourcing and In-house Manufacturing), By Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics and Marketed Therapeutics), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Personalized Genomics Market, By Test Type (Oncology Testing, Infectious Disease Testing, Neurological Testing, Cardiovascular Testing, Others), By Technology (PCR-based Tests, Microarray-based Tests, Sequencing-based Tests, Others), By Application (Diagnostics, Precision Medicine, Wellness, Reproductive Health, Sports Nutrition & Health Lifestyle, Others), By End User (Hospitals & Clinics, Research Centers, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
Cell and Gene Therapy Market, By Therapy Type, By Application, By End User, By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
CONTACT: Mr. Shah Senior Client Partner – Business Development Coherent Market Insights Phone: US: +1-206-701-6702 UK: +44-020-8133-4027 Japan: +81-050-5539-1737 India: +91-848-285-0837 Email: sales@coherentmarketinsights.com Website: https://www.coherentmarketinsights.com
